Actively Recruiting
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Led by Tianjin Medical University · Updated on 2025-02-11
200
Participants Needed
1
Research Sites
291 weeks
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
CONDITIONS
Official Title
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspected or confirmed untreated lymphoproliferative or other CXCR4-related diseases
- 18F-FDG PET/CT performed within two weeks prior to enrollment
- Signed written informed consent
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Known allergy to Pentixafor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
H
Haonan Yu, MD
CONTACT
S
Shaobo Yao, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here